Ulixacaltamide
Small molecule
Evidence outlook · regulatory review
Essential Tremor: application under FDA review, decision date 2027-01-29
FDA accepted the NDA for ulixacaltamide HCl in essential tremor (2026-04-14). A filing is the sponsor's claim that its evidence supports approval; this platform grades the trials, not the filing. The event is listed under Regulatory events.
NCT06087276: Essential3 was a randomized, triple-masked Phase 3 programme in essential tremor. Both pivotal studies met their primary endpoints according to the company's topline release. The sources read give no power calculation, so the grade is moderate.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT06087276 NCT06087276 · Essential Tremor Essential3 was a randomized, triple-masked Phase 3 programme in essential tremor. Both pivotal studies met their primary endpoints according to the company's topline release. The sources read give no power calculation, so the grade is moderate. Registry: NCT06087276 | 3 | Parallel Design: Change from Baseline (CFB) to Week 8 (Day 56) on mADL11 score (8 weeks (56 days)); Randomized Withdrawal: The proportion of participants that maintain response, as defined by change in mADL11 score, following randomized withdrawal (12 weeks (84 days)); Long-term Safety Study: Number of participants with Adverse Events (AE) and their severity. (Up to 3 years) 2025-10-10 | Both pivotal Essential3 studies met their primary endpoints: Study 1, mADL11 improvement at week 8; Study 2, maintenance of effect in randomized withdrawal (Praxis, 2025-10-16). | Partial signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (1)
What this study did
Phase 2 (2)
What this study did
What this study did
Competitive landscape
Other T-type calcium channel drugs
1 other tracked programme targets this mechanism, 1 of them ahead of this one.
This drug's own stage for Essential Tremor: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Ulixacaltamide: this drug | Phase 3 | Small molecule | T-type calcium channel | Partial signal | NCT06087276: Both pivotal Essential3 studies met their primary endpoints: Study 1, mADL11 improvement at week 8; Study 2, maintenance of effect in randomized withdrawal (Praxis, 2025-10-16). | |
| Ethosuximide | Approved(overall) | Small molecule | T-type calcium channel | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| GemibotulinumtoxinA | —(overall) | Botulinum Toxin | SNAP-25 | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
No upcoming readouts on record for this asset.
Regulatory and conference events
(3)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Coming up
Recent